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Abstract 33
Oncogenic mutations in the kinase domain of the B-Raf protein have long been associated with cancers 34
involving the RAF-MEK-ERK pathway. One constitutive ERK activating mutation in B-Raf, the V600E 35 (valine to glutamate) replacement occurring adjacent to a site of threonine phosphorylation (T599) 36 occurs in many types of cancer, and in a large percentage of certain cancers, such as melanoma. 37 Because natural ATP binding activity and the V600E mutation are both known to alter the physical 38 behavior of the activation loop in the ATP binding domain, this system is especially amenable to 39 comparative functional analyses using molecular dynamics of drug classes and genetic variants at all-40 atom resolution. Here, we employ machine learning enabled identification of functionally conserved 41 protein dynamics to compare how disease pertinent molecular variations impact conserved loop 42 dynamics during the binding of four ATP competitive B-Raf inhibitors (sorafenib, vemurafenib, 43 dabrafenib, and PLX7904) that differ in their effectiveness in preventing cancer recurrence. We 44 demonstrate that drug development targeting B-Raf has progressively moved towards ATP competitive 45
inhibitors that demonstrate less tendency to mimic the functional dynamic shifts associated with ATP 46 binding in this domain. We argue this functional dynamic mimicry in first generation B-Raf inhibitors 47
increases the side effect of hyperactivation (i.e. inducing MAPK activation in non-tumorous cells in the 48 absence of secondary mutation). Within the context of the binding interaction of each inhibitor, we 49 compare the functional dynamic impacts of V600E and other sensitizing and drug resistance causing 50 mutations in the activation and P-loops, confirming sites of low mutational tolerance in these two 51 functional regions. Lastly, we investigate V600E sensitivity of B-Raf loop dynamics in an evolutionary 52 context, demonstrating that while it probably shares partial origin with its early evolution in primitive 53 eukaryotes, the functional sensitivity to V600E was secondarily increased during early jawed vertebrate 54 evolution.
55
Author Summary 56 Our lab has recently developed a combined simulation-based and machine learning method and user-57 friendly software for identifying dynamic motions in proteins that are preserved over evolutionary time 58 scales (i.e. are functionally conserved). Our method also can assess how genetic or chemical variation 59 affects these functionally conserved motions. Here, we utilize this approach to computationally 60 demonstrate how one of the most common mutations that arise in tumors, the V600E B-Raf protein 61 mutation, disrupts the functioning of protein loop dynamics responsible for normal regulation of the 62 oncogenic B-Raf protein and its growth signaling pathway. We demonstrate that cancer recurrence in 63 the absence of new mutations may be caused by drug interactions impacting these dynamics. We 64
propose that mimicry of the functional dynamics of natural chemical activators (i.e. agonists) by many 65 cancer targeting drugs may be a potent causal factor in recurrence of cancer in the absence of 66 secondary mutation. By combining comparative modeling of molecular dynamics and analyses of 67 molecular evolution, we also demonstrate that the unusual sensitivity of B-Raf protein regulatory loop 68 dynamics to this mutation has an ancient evolutionary origin.
Introduction 73
From both a patient's and doctor's perspective, perhaps the most dreaded aspect of many cancers are 74 their ability to undergo recurrence following therapeutic intervention. The recurrence of cancer can 75 have obvious negative impact on patient psychology [1,2], doctor-patient relations [3] and questions the 76 very concept of a 'cure' for cancer. The molecular mechanisms and somatic evolutionary processes that 77 underlie the phenomena of recurrence are complex and do not act singularly within any given tumor, 78 thereby greatly exacerbating the clinical difficulty of treatment and post-treatment monitoring. There 79 are currently three molecular mechanistic frameworks for potentially explaining cancer recurrence. The 80 traditional view of 'mutational deregulation' invokes a progressive molecular evolutionary Fisherian or 81 'runaway' process whereby tumor progression begins with one or several 'driver mutations' that start a 82 cascade of secondary mutation and subsequent deregulation of growth and proliferation followed by 83 eventual chromosomal disruption through aneuploidy and chromothrypsis [4] . Under this conceptual 84 framework, cancer progression is largely due to a mutational process that progressively deregulates cell 85 proliferation and frames cancer recurrence as a problem analogous to a 'whack a mole' game that gets 86 more difficult as the game progresses. activating mutations, and of these 90% involve the three bases of codon 600, and of these 90% are the 138 single nucleotide missense mutation at position 1799 resulting in V600E substitution (although V600 K, 139 D, R have also been less commonly observed [19] ).
140

Fig 1. Overview of role of BRAF in mitogen-activated protein kinase pathway (MAPK) pathway. 141
Growth factor/s binds to the receptor (EGFR) on the cell surface which leads to phosphorylation and 142 subsequent activation. between Figure 1B and Supplemental Figure 4A ). While the modern inhibitors have dFLUX profiles 230 somewhat similar to that of ATP, they all differ in key respects. Vemurafenib and dabrafenib also seem 231 to affect P loop dynamics in ways that are very different than ATP (position 460-468 in Supplemental 232 Figure 4B and 4C), while vemurafenib and PLX7904 exhibits more global disruption and dampening of 233 dynamics across the whole B-Raf binding domain (indicated by widespread negative dFLUX in 234
Supplemental Figure 4B and 4D). Figure 5A ). This effect was larger toward the C terminal regions of the protein. In the 283 mutant background, Vemurafenib appeared to mimic the functional effect of ATP binding similar to 284 wildtype, but too a much larger degree, confirming a potential indication of its well-known selectivity to 285 mutant B-Raf (Supplemental Figure 5B ). Upon its interaction with the binding pocket, Dabrafenib 286 induced strong stabilization in the area of the catalytic and activation loops, locking B-Raf into its open 287 confirmation and perhaps enhancing its well-known effect as an ATP competitor (Supplemental Figure  288 5C). Alternatively, upon binding the mutant, PLX7904 exhibited large destabilizations of the P-loop, ATP 289 binding pocket and the regions extending from the activation loop and the region of residue 650-680 290
that freezes the open confirmation in the absence of the drug (Supplemental Figure 5D ). Close-up 291
images of the impacts on B-Raf inhibitor binding on conserved protein dynamics in the loop regions are 292
shown in Supplemental Figure 6 . We note that PLX7904, as the paradox breaking inhibitor, shows 293 substantially less activity near the V600 region and activating segment in general, as it was constructed 294
to disrupt overall B-Raf structure and affect dimerization, particularly targeting the L505 position, in 295 order to affect the helix there. In our study, we find that the region near 490-505 appear to be 296 selectively affected by disruptions to dynamics, suggesting a dynamic mechanism for its previously 297 observed hyperactivation paradox breaking behavior. investigate the presence of quasi-stable dynamic states. In most cases, the dFLUX (i.e. KL divergence) 311 profiles in these runs matched that of longer runs. However, we did occasionally encounter a less 312 common dFLUX profile around the V600 site, indicating strongly biphasic dynamic behavior in this 313 region. In this situation, the typical combination of dampened and normal amplification of atom 314 fluctuation (Supplemental Figure 7A) is replaced by only strong amplification at the same site 315 (Supplemental Figure 7B ). This potentially indicated the presences of very complex biphasic, or 'switch-316 like' behavior of the dynamics in the region where V600E sensitivity occurs.
317
Supplemental Figure 7. Natural biphasic behavior of the activation loop captured by comparative 318 molecular dynamic analysis of PLX7904 binding interaction in mutant V600E B-Raf kinase domain (PDB ID = 4xv1). Colored circled regions indicate the P-loop (red), ATP binding pocket (blue), catalytic loop 320 (green) and a highly flexible activation loop (yellow). The activation loop is shown in two stable states, 321 (A) open conformation with and highly flexible activation loop, and (B) closed conformation with highly 322
dampened activation loop. NOTE: simulation runs were averaged over only 20x0.1ns production runs (i.e. 323 fewer sampling runs taken over shorter time periods than training sets in Figure 2 and 3) . Table 1 , Figures 4-7) . During the interaction of hyperactivation-inducing 330 sorafenib with the ATP binding pocket, dynamic shifts in the activation loop are clearly evident (as large 331 positive and negative dFLUX values in Figure 4A ) which are quite similar in effect to changes in this 332 region caused by ATP binding (Figure 2A ). Functional dynamic shifts identified by our machine learning 333 model are also quite evident upon sorafenib binding ( Figure 4B -C) and similarly connect the ATP binding 334 pocket to the outer bend of the activation loop when ATP binds ( Figure 2B ). The V600E mutation which 335 sensitizes sofafenib targeting to B-Raf, was found to greatly impact loop dynamics when compared to 336 validation runs with no mutation ( Figure 4D ) and corroborating its large impact on functional dynamics 337 in general (Figure 3) . The three remaining drug resistant mutations (G464V, G469E, G469V) show less 338
impact, but are collectively larger than validation, suggesting that mutations disrupting dynamics of the 339 P loop are key in creating drug resistance to sorafenib ( Figure 4D ). In stark contrast to the sorafenib 340 results, the hyperactivation-breaking compound, PLX7904, while also causing similar dynamics shifts to 341 the activation loop ( Figure 5A ), fails to produce hardly any dynamic changes that are identified as 342 functional by our machine learning classification model ( Figure 5B-C) . Thus, it appears that while 343 PLX7904 is a potent competitive binder to mutant B-Raf, it also has the benefit of potentially disrupting 344 any functional dynamics that could allow stable interactions with other components of the MAPK 345 pathway. Our analysis of mutational impacts on functional dynamics ( Figure 4D ) also support this, and 346 suggest that changes in PLX7904 efficacy caused by mutation are likely independent of the normal 347 evolutionary conserved function of B-Raf. Analysis of vemurafenib ( Figure 6 ) shows marked similarity to 348 sorafenib, suggesting that it is also prone to mimic the functional dynamics of ATP binding ( Figure 6B -C) 349 but with softening of the P-loop as well ( Figure 6A ). A survey of 18 drug impacting mutations does not 350
show any clear trend except that mutational impacts are largest in regions affecting either the P-loop or 351 the activation loop ( Figure 6D ). Similar analysis of dabrafenib indicates a hardening of P-loop dynamics 352 ( Figure 7A ) and a pattern of less coordinated impact on conserved dynamics that fails to connect the 353 ATP binding pocket to the activation loop ( Figure 7B-C 
Phylogenetic analysis of V600E sensitivity regarding B-Raf loop dynamics
396
A minimum evolution tree ( Figure 8A ) and maximum likelihood tree (supplemental Figure 8 ) was used to 397 identify protein level variants for tetrapod (= human), ray-finned fish, and insect. The wildtype genetic 398 backgrounds incorporating 9 amino acid replacements (fish) and 95 replacements (insect) show no 399 elevated dynamic impacts over the validation run (wildtype tetrapod). However, V600E/A600E mutants 400 both demonstrate elevated disruption of conserved ATP binding dynamics ( Figure 8B) indicating that B-401
Raf sensitivity to this mutation has an ancient origin. The very large increase in dynamic impact of V600E 402 in ray-finned fish over that of A600E in insects indicates a large increase in V600E sensitivity in early 403 jawed vertebrate evolution as well ( Figure 8B ). Local mapping of these impacts ( Figure 8C) indicates 404 involvement of all three functional regions (P-loop at position 13-25, ATP binding pocket at position 60-405 100, and activation loop at position 153-190) in the functional evolution of this sensitivity. The dynamic 406
impacts of V600E and A600E in these ancient backgrounds are also shown color-mapped to the B-Raf 407 structure ( Figure 8D and 8E resp.).
408 Fig 8. Comparative molecular dynamic analysis Given their involvement in a variety of cellular processes, protein kinases, specifically serine/threonine 428 kinases play a role in all of the major cancers. Many serine/threonine kinases have altered expression in 429 tumors [24] . Given that this class of enzyme is a proven putative and attractive target for the 430 development of cancer therapies, our study of the function and evolution of the molecular dynamics of 431 the serine/threonine kinase B-Raf has the potential to guide future studies and experiments aimed at 432 elucidating efficacy and rationale design of therapeutics. Through our novel high performance 433
computing approach to machine learning applied to comparative functional molecular dynamics 434 simulations, we have demonstrated that ATP binding to the CR3 domain of B-Raf protein induces 435 evolutionarily functionally conserved changes in dynamics that physically connect ATP binding pocket 436 with both the P-loop and activation segment. The region just downstream of the mutation intolerant 437 valine codon 600 is especially affected in its dynamics by ATP binding remotely on the structure of the 438 protein KD. The V600E mutation massively disrupts these evolutionary conserved shifts in dynamics that 439 are obviously a key complex functional feature of BRAF signaling and MAPK regulation. dynamics are still potentially in play, albeit likely subverted into a malfunctional state from the 453 standpoint of the patient. However, PLX7904 currently has very few known sensitizing or resistant 454
mutations, an observation that may reflect lack of experimentation with the new compound, but may 455 also prove consistent with our demonstration that it largely avoids inducing the same sort of dynamic 456 changes as ATP upon binding the same location. Finally, our molecular evolutionary study, indicates that 457 B-Raf sensitivity to V600E has a likely ancient origin, perhaps as old as the Raf kinase protein family 458
itself. However, the sensitivity of functionally conserved B-Raf dynamics to V600E, appears to have 459 greatly increased sometime during early jawed vertebrate evolution, as represented by extant 460 sequences across all modern ray-finned fishes. As a modulator of multicellular growth, B-Raf likely has 461 origins in early eukaryotes, however poor alignment quality to putative orthologs in C. elegans and S. 462 cerevisiae prevented us from exploring this possibility further.
463
Conclusion 464 We propose that functional dynamic mimicry (FDM), as observed here in B-Raf inhibitors, is an 465 important risk factor to consider in future rational drug design. This an especially important 466 consideration when targeting sites of natural agonists involved in signal activation in pathways like 467 MAPK which are typically downregulated after early embryonic development, and a subsequently 468 problematic in all cancers. Pharmaceuticals that avoid FDM while effectively targeting and binding active 469 sites of proteins in these pathways, are most likely disrupting the functional dynamics of protein 470
domains to the extent that they are no longer recognized by the pathways in which they normally 471 participate. In the case of pathways downregulated after early development, this affect is ideal, as it 472 destroys signal transduction. Our DROIDS 3.0 + maxDemon 1.0 computational software [22, 23] can 473 allow for inexpensive screening against unintended effects of FDM, potentially producing better patient 474 products while saving pharmaceutical industry wasted time, effort and money in preclinical 475 development and clinical trial. We also conclude that a more evolutionary and biophysical perspective 476 around complex problems like FDM that are potentially linked to naturally evolved tolerances to protein 477 mutation are greatly needed in future biomedical research. This cannot be easily addressed by the 478 combination of DNA sequence-based bioinformatics and cell/animal-based experimental research alone. 479
Proteins are nanometer sized machines operating in the complex context of soft matter dynamics. They 480 are often imperfect in their interactions with other proteins and incompletely optimized in terms of 481 their functional evolution. The development of modern drug therapies could benefit by embracing a 482 more functional evolutionary perspective that is grounded in computational biophysical method. The reference state of the protein is unbound while the query state is bound. Therefore, this pairwise 549 comparison is used to represent the functional impact of ligand binding on the protein's normal 550 unbound motion, where it is expected that ligand contacts would typically dampen the fluctuation of 551 atoms around the ATP binding pocket to some degree. As ATP binding acts to destabilize the activation 552 loop and P-loop regions of B-Raf, this analysis will allow quantification of dynamic impacts that amplify 553 loop motions as well.
554
Machine learning performance and detection of conserved dynamic function 555 We applied machine learning analysis to examine normal ATP binding in wildtype B-Raf. We then 556 compare these results to a similar analysis of ATP binding in V600E mutants to ascertain how this 557 mutation alters functionally conserved dynamics in the B-Raf protein system. The detection of 558 functionally conserved protein dynamics in wildtype B-Raf followed the machine learning-based method 559 outlined in our previous DROIDS 3.0 + maxDemon 1.0 software papers [22, 23] . In summary, a stacked 560 machine learning model implementing seven classification methods (K nearest neighbors, naïve Bayes, 561 linear/quadratic discriminant analysis, support vector machine, random forest and adaptive boosting) 562 was individually trained upon each amino acid's fluctuation data that was pre-classified to the ligand 563 bound and the unbound dynamic states. These learners were deployed upon the identical amino acids 564 within two new 5ns MD simulations of the ligand bound structure and classifications of atom fluctuation 565 (i.e. rmsf calculated for 500 x 0.01 ns time slices) where 0 = unbound and 1 = bound states were 566
averaged to obtain a learning performance value for each amino acid. Average learning performance 567 profiles (i.e. accuracy and precision) are generated along the protein from N to C terminus. Note that a 568 value of 0.5 at a given position would indicate that the learning model could not differentiate between 569
bound and unbound dynamics at that residue. Local significant canonical correlations in learning 570 performance between the two validation runs on the ligand bound structure indicate where any 571 position-dependent molecular dynamics that is functionally conserved with regards to the binding 572 interaction has occurred. The correlation was calculated within a 20 residue sliding window along the 573 learning profile.
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The central concept here is that if any atom motion is specific to a given functional state (i.e. in 576 this case protein bound to ligand, vs unbound protein), then after training, the machine learners will be 577 able to successfully classify this motion when it is observed in subsequent identical validation MD runs. 578
When the learners are able to repeatedly identify functional state dynamics that locally associate with a 579 specific position on the protein, this will create correlated profiles in learning performance. As our 580 machine learning model is a stacked model, incorporating seven learning algorithms, it is more robust to 581 artifacts related to any single method, and the resulting correlation is canonical as well (see 582
Supplemental Figure 1 for an example of correlated and uncorrelated sets of learning profiles). We can 583 label the dynamics as 'functionally conserved' if the machine learning model can consistently identify 584 the functional dynamic states upon which it trained across multiple and independent validation runs. 585
Two or more identically prepared validation runs are used to examine whether statistically significant 586 canonical correlations (i.e. conserved dynamics) are locally identifiable by a significant local Wilk's 587 lambda value for a local canonical correlation coefficient.
588
Method of genetic and drug variant impact assessment
589
The local impacts of mutations and drug class variants were obtained by first deriving the canonical 590 correlation of the learner performance profile of a given variant to the wildtype B-Raf in its normal 591 functionally bound state (= CC variant ). This also uses a 20 residue sliding window. The impact metric is 592 generated by comparing canonical correlation of the variant (CC variant ) to the self-similar dynamic 593 correlation (CC self ) defining functionally conserved dynamics above, using the common definition of 594 relative entropy below 595 = *
596
Effectively, this impact metric captures the difference in conserved dynamics between the wildtype 597 ligand bound state (here ATP or one of the four Raf inhibitors) and the variant states of binding created 598 by genetic mutation or different drug ligand molecules. This occurs on the same scale as that used to 599 differentiate bound from unbound states during the earlier training of the stacked learning model. More 600 details regarding our methodological approach to identifying functionally conserved dynamics and 601 subsequent impacts of genetic and drug class variants can be obtained in our prior publication [22, 23] .
602
The relative impacts of four B-Raf inhibitors, sorafenib, dabrafenib, vemurafenib and PLX7904 603
were assessed after initially training the stacked machine learning model on ATP bound and unbound B-
